Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | PAM | P19021 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 3/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768507 | 1.00 | TSHR (0.60) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL3503234 | 0.84 | TSHR (0.66) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL3505613 | 0.84 | TSHR (0.66) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL2958192 | 0.84 | TSHR (0.66) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL2418388 | 0.82 | TSHR (0.62) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL5668563 | 0.80 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126642 | 0.80 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL20570495 | 0.80 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL10411 | 0.80 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA | |
| SCHEMBL22126641 | 0.80 | TSHR (0.70) | TSHRDGKAPAMMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112624920-B | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-112624920-A | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-112624920-B | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-112624920-B | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-112624920-B | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-111484409-B | Preparation method of 2-methyl-4-substituted carbonyloxy-2-butenal | 新发药业有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-111484525-B | Vitamin A ester intermediate C15 and preparation method of vitamin A ester | 新发药业有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-112624920-A | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112624920-A | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-112624920-A | Synthesis method of 4-palmitoyloxy-2-methyl-2-butenal and synthesis method of vitamin A palmitate | 北京藏卫信康医药研发有限公司 | 2021-04-09 | — | — | CN | disclosed |
| CN-111484525-A | Vitamin A ester intermediate C15 and preparation method of vitamin A ester | 新发药业有限公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-111484409-A | Low-cost preparation method of 2-methyl-4-substituted carbonyloxy-2-butenal | 新发药业有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-6727381-B2 | REACTING PHOSPHONATE COMPOUND WITH ALDEHYDE IN ORGANIC SOLVENT (HEXANE) IN PRESENCE OF A BASE (SODIUM TERT-BUTOXIDE) | ZHEJIANG MEDICINE CO., LTD., XINCHANG PHARMACEUTICAL FACTORY (CN) | 2004-04-27 | — | — | US | disclosed |
| US-20020151742-A1 | Process for producing vitamin a ester | ZHEJIANG MEDICINE CO., LTD. (CN) | 2002-10-17 | — | — | US | disclosed |
| US-5424478-A | Process for producing vitamin A derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151742-A1 | Process for producing vitamin a ester | TTPA, ADH1B, ADH4 | TSHR 2055/4885DGKA 902/4885PAM 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.